Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).
UW-SES: A new self-efficacy scale for people with disabilities.
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis
Metabolic features of the cell danger response.
Gait variability measures reveal differences between multiple sclerosis patients and healthy controls.
Opposing Effects of Membrane-Anchored CX3CL1 on Amyloid and Tau Pathologies via the p38 MAPK Pathway.
3D models of human ERα and ERβ complexed with coumestrol.
Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic.
Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis.
Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
SMC Says Yes to Lemtrada(R)a- 1/4 (alemtuzumab) 12mg IV, a New Treatment for Adults with Active Relapsing Remitting-Multiple Sclerosis (RRMS)
Neuromyelitis optica.
The effect of Nintendo(R) Wii(R) on balance in people with multiple sclerosis: a pilot randomized control study.
Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Safety Study of GNbAC1 in Multiple Sclerosis Patients
Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis.
Teva Announces Approval of Three-Times-A-Week COPAXONE® 40 mg/mL in Russia for the Treatment of Relapsing-Remitting Multiple Sclerosis
Genmab announces details of planned ofatumumab Phase II study in multiple sclerosis
Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis.
Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine.
Extracranial Venous abnormalities: A true pathological finding in patients with multiple sclerosis or an anatomical variant?
Apitope Announces Completion of Enrolment in Phase IIA Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis

Pages